OBJECTIVES: To assess the effect of self monitoring of blood glucose concentrations on glycaemic control and psychological indices in patients with newly diagnosed type 2 diabetes mellitus. DESIGN: Prospective randomised controlled trial of self monitoring versus no monitoring (control). SETTING:Hospital diabetes clinics. PARTICIPANTS: 184 (111 men) people aged <70 with newly diagnosed type 2 diabetes referred to the participating diabetes clinics. Major exclusion criteria were secondary diabetes, insulin treatment, previous self monitoring of blood glucose. INTERVENTIONS: Participants were randomised to self monitoring or no monitoring (control) groups for one year with follow-up at three monthly intervals. Both groups underwent an identical structured core education programme. The self monitoring group received additional education on monitoring. MAIN OUTCOME MEASURES: Between group differences in HbA(1c), psychological indices, use of oral hypoglycaemic drugs, body mass index (BMI), and reported hypoglycaemia rates. RESULTS:96 patients (55 men) were randomised to monitoring and 88 (56 men) to control. There were no baseline differences in mean (SD) age (57.7 (11.0) in monitoring group v 60.9 (11.5) in control group) or HbA(1c) (8.8 (2.1)% v 8.6 (2.3)%, respectively). Those in the monitoring group had a higher baseline BMI (34 (7) v 32 (6.2)). There were no significant differences between groups at any time point (12 months values given) in HbA(1c) (6.9 (0.8)% v 6.9 (1.2)%, P=0.69; 95% confidence interval for difference -0.25% to 0.38%), BMI (33.1 (6.4) v 31.8 (6.0); adjusted for baseline BMI, P=0.32), use of oral hypoglycaemic drugs, or reported incidence of hypoglycaemia. Monitoring was associated with a 6% higher score on the depression subscale of the well-being questionnaire (P=0.01). CONCLUSIONS: In patients with newly diagnosed type 2 diabetes self monitoring of blood glucose concentration has no effect on glycaemic control but is associated with higher scores on a depression subscale. TRIAL REGISTRATION: ISRCTN 49814766.
RCT Entities:
OBJECTIVES: To assess the effect of self monitoring of blood glucose concentrations on glycaemic control and psychological indices in patients with newly diagnosed type 2 diabetes mellitus. DESIGN: Prospective randomised controlled trial of self monitoring versus no monitoring (control). SETTING: Hospital diabetes clinics. PARTICIPANTS: 184 (111 men) people aged <70 with newly diagnosed type 2 diabetes referred to the participating diabetes clinics. Major exclusion criteria were secondary diabetes, insulin treatment, previous self monitoring of blood glucose. INTERVENTIONS:Participants were randomised to self monitoring or no monitoring (control) groups for one year with follow-up at three monthly intervals. Both groups underwent an identical structured core education programme. The self monitoring group received additional education on monitoring. MAIN OUTCOME MEASURES: Between group differences in HbA(1c), psychological indices, use of oral hypoglycaemic drugs, body mass index (BMI), and reported hypoglycaemia rates. RESULTS: 96 patients (55 men) were randomised to monitoring and 88 (56 men) to control. There were no baseline differences in mean (SD) age (57.7 (11.0) in monitoring group v 60.9 (11.5) in control group) or HbA(1c) (8.8 (2.1)% v 8.6 (2.3)%, respectively). Those in the monitoring group had a higher baseline BMI (34 (7) v 32 (6.2)). There were no significant differences between groups at any time point (12 months values given) in HbA(1c) (6.9 (0.8)% v 6.9 (1.2)%, P=0.69; 95% confidence interval for difference -0.25% to 0.38%), BMI (33.1 (6.4) v 31.8 (6.0); adjusted for baseline BMI, P=0.32), use of oral hypoglycaemic drugs, or reported incidence of hypoglycaemia. Monitoring was associated with a 6% higher score on the depression subscale of the well-being questionnaire (P=0.01). CONCLUSIONS: In patients with newly diagnosed type 2 diabetes self monitoring of blood glucose concentration has no effect on glycaemic control but is associated with higher scores on a depression subscale. TRIAL REGISTRATION: ISRCTN 49814766.
Authors: A Fontbonne; B Billault; M Acosta; C Percheron; P Varenne; A Besse; E Eschwege; L Monnier; G Slama; P Passa Journal: Diabete Metab Date: 1989 Sep-Oct
Authors: M Franciosi; F Pellegrini; G De Berardis; M Belfiglio; D Cavaliere; B Di Nardo; S Greenfield; S H Kaplan; M Sacco; G Tognoni; M Valentini; A Nicolucci Journal: Diabetes Care Date: 2001-11 Impact factor: 19.112
Authors: Andrew Farmer; Alisha Wade; Elizabeth Goyder; Patricia Yudkin; David French; Anthea Craven; Rury Holman; Ann-Louise Kinmonth; Andrew Neil Journal: BMJ Date: 2007-06-25
Authors: B Guerci; P Drouin; V Grangé; P Bougnères; P Fontaine; V Kerlan; P Passa; Ch Thivolet; B Vialettes; B Charbonnel Journal: Diabetes Metab Date: 2003-12 Impact factor: 6.041
Authors: Somesh Nigam; Naunihal S Virdi; Mehmet Daskiran; Chris M Kozma; Andrew Paris; William M Dickson Journal: J Diabetes Sci Technol Date: 2012-05-01
Authors: Tara Gomes; Diana Martins; Lucy Cheng; Jillian Kratzer; David N Juurlink; Baiju R Shah; Muhammad M Mamdani; J Michael Paterson; Michael R Law Journal: Can J Public Health Date: 2015-04-30